Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDA Reviews To Be Studied Prospectively To Identify Best First-Cycle Practices

This article was originally published in The Tan Sheet

Executive Summary

FDA is planning a prospective study on the root causes of multiple-cycle drug and biologic reviews as part of an effort to improve the review process, Commissioner Mark McClellan, MD/PhD, announced Jan. 31
Advertisement

Related Content

FDA Has “Issues” With NDAs; Half Of 74-Day Letters Note Application Flaws
FDA Has “Issues” With NDAs; Half Of 74-Day Letters Note Application Flaws
FDA Has “Issues” With NDAs; Half Of 74-Day Letters Note Application Flaws
PDUFA III “Good Review Management Principles” Stress Early FDA Action
PDUFA III “Good Review Management Principles” Stress Early FDA Action

Topics

Advertisement
UsernamePublicRestriction

Register

PS095090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel